Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of ...

Novo Nordisk rebounds from 2024 lows as GLP-1 supply issues ease, partnerships expand, and valuation turns attractive. Find ...

A long-term shift in U.S. calorie consumption, spurred by rising use of GLP-1 weight-loss drugs, could reduce packaged food and beverage volumes by more than 10%, Bank of America said.

CHICAGO -- An investigational, oral small-molecule GLP-1 receptor agonist improved glycated hemoglobin levels in adults with ...

With semaglutide and tirzepatide dosed once weekly, their estimated average yearly costs in the U.S. are $14,080 and $8,126, ...

A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who ...

In a move that could reshape how doctors approach both weight and heart health, the American College of Cardiology (ACC) ...

More than 90% of patients achieved clinically meaningful weight reduction compared to placebo in a phase 3 trial of ecnoglutide.

Glucagon-Like-Peptide-1 Agonists, like Ozempic, have become extremely popular for weight loss. Here are some of the side ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new ...

That is according to the findings of a study presented on Friday at the European Academy of Neurology congress. The pilot ...